TherapeuticsMD Inc. (NASDAQ:TXMD) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 0.10% to the previous day’s close as strong demand from buyers drove the stock to $9.90.
Actively observing the price movement in the last trading, the stock closed the session at $9.89, falling within a range of $9.88 and $10.022. The value of beta (5-year monthly) was 1.90. Referring to stock’s 52-week performance, its high was $64.50, and the low was $1.99. On the whole, TXMD has fluctuated by 219.35% over the past month.
With the market capitalization of TherapeuticsMD Inc. currently standing at about $86.53 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 28, 2022 – Mar 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$4, which is expected to increase to -$2 for fiscal year -$4.08 and then to about -$0.78 by fiscal year 2023. Data indicates that the EPS growth is expected to be 81.00% in 2023, while the next year’s EPS growth is forecast to be 80.90%.
Analysts have estimated the company’s revenue for the quarter at $17.95 million, with a low estimate of $16.3 million and a high estimate of $19.61 million. According to the average forecast, sales growth in current quarter could jump down -9.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $113.94 million, representing an increase of 31.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TXMD’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TXMD currently trading nearly 23.69% and 14.54% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.10, while the 7-day volatility ratio is showing 1.90% which for the 30-day chart, stands at 5.00%. Furthermore, TherapeuticsMD Inc. (TXMD)’s beta value is 1.86, and its average true range (ATR) is 0.47.
A comparison of TherapeuticsMD Inc. (TXMD) with its peers suggests the former has fared considerably weaker in the market. TXMD showed an intraday change of 0.10% in last session, and over the past year, it shrunk by -83.36%%. In comparison, AbbVie Inc. (ABBV) has moved higher at 2.85% on the day and was up 28.65% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has risen 2.00% on the day. The stock, however, is off 23.88% from where it was a year ago. Additionally, there is a loss of -5.22% for Agile Therapeutics Inc. (AGRX) in last trading while the stock has seen an overall depriciation of -97.97%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.15%.
Data on historical trading for TherapeuticsMD Inc. (NASDAQ:TXMD) indicates that the trading volumes over the past 10 days have averaged 1.12 million and over the past 3 months, they’ve averaged 1.04 million. According to company’s latest data on outstanding shares, there are 424.93 million shares outstanding.
Nearly 0.10% of TherapeuticsMD Inc.’s shares belong to company insiders and institutional investors own 29.60% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.76 million shares as on Apr 28, 2022, resulting in a short ratio of 6.28. According to the data, the short interest in TherapeuticsMD Inc. (TXMD) stood at 8.74% of shares outstanding as of Apr 28, 2022; the number of short shares registered in Mar 30, 2022 reached 0.62 million. The stock has fallen by -44.30% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TXMD stock heading into the next quarter.